Evidence map›Paper›PMID 37215361›Full record

ArticleIIC; international review of industrial property and copyright law2023

Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer?

Żaneta Zemła-Pacud, Gabriela Lenarczyk

Abstract read
In one paragraph

Article in IIC; international review of industrial property and copyright law, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Żaneta Zemła-PacudWarsaw, Poland Dr.; Department of Polish and European Industrial Property Law, Polish Academy of Sciences.ORCID 0000-0002-3131-9466
Gabriela LenarczykWarsaw, Poland Dr.; Department of Private Law, Institute of Law Studies, Polish Academy of Sciences.ORCID 0000-0001-5965-7291

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The benefits of access to clinical trial data are related to their inestimable value from the perspective of clinical trial participants, society as a whole, public health systems and scientific progress. In light of the development of innovative data analysis technologies, access to raw clinical trial data opens up an ever-widening array of possibilities: it can profoundly facilitate machine data analysis for,

Indexed as

Clinical trial dataClinical trial data transparencyClinical Trials RegulationCommercially confidential informationCTIS

Identifiers

PMID37215361
PMCPMC10158712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.